Kenneth Mills Biography and Net Worth

CEO of REGENXBIO

Kenneth T. Mills has been our President, Chief Executive Officer and Director since March 2009. Mr. Mills was with FOXKISER LLP (“FOXKISER”), most recently as a Partner, from January 2007 to January 2015. Mr. Mills was previously the Chief Financial Officer and Vice President of Business Development at Meso Scale Diagnostics, a life sciences company, from January 2004 to December 2006 and was part of the original management team that established the company’s operations and financing strategy. From March 1997 to December 2003, Mr. Mills was employed at IGEN, a biotechnology company, where he served as Director of Business Development up through the company’s acquisition by Roche. Mr. Mills received an S.B. in Chemistry from the Massachusetts Institute of Technology. Mr. Mills’ qualifications to continue to serve as a member of the Board include his extensive experience as an executive in the gene therapy and biotechnology industries, including as President and Chief Executive Officer of our Company, his prior service as a senior-level executive in both early stage and mature biotechnology companies and his demonstrated business judgment. Provided by Tagnifi.

What is Kenneth T. Mills' net worth?: The estimated net worth of Kenneth T. Mills is at least $3.35 million as of July 24th, 2024. Mr. Mills owns 408,035 shares of REGENXBIO stock worth more than $3,349,967 as of March 25th. This net worth evaluation does not reflect any other investments that Mr. Mills may own. Learn More about Kenneth T. Mills' net worth.
How do I contact Kenneth T. Mills?: The corporate mailing address for Mr. Mills and other REGENXBIO executives is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. REGENXBIO can also be reached via phone at (240) 552-8181 and via email at ir@regenxbio.com. Learn More on Kenneth T. Mills' contact information.
Has Kenneth T. Mills been buying or selling shares of REGENXBIO?: Kenneth T. Mills has not been actively trading shares of REGENXBIO during the last quarter. Most recently, Kenneth T. Mills sold 12,221 shares of the business's stock in a transaction on Wednesday, July 24th. The shares were sold at an average price of $13.78, for a transaction totalling $168,405.38. Following the completion of the sale, the director now directly owns 408,035 shares of the company's stock, valued at $5,622,722.30. Learn More on Kenneth T. Mills' trading history.
Who are REGENXBIO's active insiders?: REGENXBIO's insider roster includes Allan Fox (Director), Kenneth Mills (CEO), Kenneth Mills (CEO), and Steve Pakola (Insider). Learn More on REGENXBIO's active insiders.
Are insiders buying or selling shares of REGENXBIO?: In the last twelve months, insiders at the biotechnology company sold shares 11 times. They sold a total of 105,279 shares worth more than $1,486,734.00. The most recent insider tranaction occured on October, 1st when Director Argeris N Karabelas sold 10,000 shares worth more than $101,100.00. Insiders at REGENXBIO own 13.1% of the company. Learn More about insider trades at REGENXBIO.
Information on this page was last updated on 10/1/2024.

Kenneth T. Mills Insider Trading History at REGENXBIO

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/24/2024	Sell	12,221	$13.78	$168,405.38	408,035
7/17/2024	Sell	2,210	$13.77	$30,431.70	408,035
5/14/2024	Sell	15,000	$15.81	$237,150.00	408,035
4/15/2024	Sell	15,000	$18.19	$272,850.00	408,035
3/14/2024	Sell	15,000	$21.86	$327,900.00	408,035
2/14/2024	Sell	15,000	$16.76	$251,400.00	408,035
1/16/2024	Sell	45,000	$15.18	$683,100.00	408,035
12/19/2023	Sell	45,000	$19.68	$885,600.00	355,289
11/8/2021	Sell	1,500	$40.00	$60,000.00
9/27/2021	Sell	1,500	$42.19	$63,285.00
6/24/2021	Sell	4,500	$40.02	$180,090.00	285,484
1/25/2021	Sell	6,500	$44.74	$290,810.00	287,484
1/7/2021	Sell	1,500	$50.01	$75,015.00	283,484
12/23/2020	Sell	4,500	$50.00	$225,000.00	245,500
12/16/2020	Sell	15,000	$45.00	$675,000.00	256,000
12/10/2020	Sell	4,500	$40.00	$180,000.00	245,500
9/19/2019	Sell	10,000	$39.75	$397,500.00	251,000
8/19/2019	Sell	15,000	$37.55	$563,250.00	261,000
7/19/2019	Sell	15,000	$49.49	$742,350.00	261,000
6/19/2019	Sell	15,000	$52.54	$788,100.00	261,000
5/20/2019	Sell	15,000	$42.99	$644,850.00	261,000
4/22/2019	Sell	15,000	$50.44	$756,600.00	261,000
3/19/2019	Sell	15,000	$58.53	$877,950.00	261,000
2/15/2019	Sell	15,000	$47.29	$709,350.00	261,000
1/15/2019	Sell	15,000	$43.85	$657,750.00	204,140
12/17/2018	Sell	15,000	$46.73	$700,950.00	223,396
11/26/2018	Sell	20,000	$64.17	$1,283,400.00	259,620
11/21/2018	Sell	15,000	$61.44	$921,600.00	284,700
11/12/2018	Sell	20,000	$63.11	$1,262,200.00
11/5/2018	Sell	20,000	$68.25	$1,365,000.00	322,500
10/15/2018	Sell	7,510	$59.35	$445,718.50	331,710
9/17/2018	Sell	7,510	$74.91	$562,574.10	339,505
8/27/2018	Sell	7,510	$66.46	$499,114.60	348,530
6/20/2018	Sell	5,000	$66.20	$331,000.00	208,330
5/21/2018	Sell	10,000	$47.05	$470,500.00
4/20/2018	Sell	10,000	$39.52	$395,200.00	219,430
3/20/2018	Sell	10,000	$29.55	$295,500.00	228,530
2/20/2018	Sell	10,000	$26.56	$265,600.00	238,530
1/22/2018	Sell	10,000	$27.33	$273,300.00	248,530
12/20/2017	Sell	10,000	$31.75	$317,500.00	108,530
11/20/2017	Sell	10,000	$27.71	$277,100.00
10/20/2017	Sell	10,000	$32.62	$326,200.00	98,730
9/20/2017	Sell	10,000	$29.33	$293,300.00	108,630
9/5/2017	Sell	10,500	$25.00	$262,500.00	118,530
8/21/2017	Sell	6,500	$20.05	$130,325.00	105,500
7/20/2017	Sell	6,500	$18.66	$121,290.00	112,000
6/20/2017	Sell	6,500	$19.68	$127,920.00	119,396
4/24/2017	Sell	15,440	$20.98	$323,931.20	126,395

See Full Table

Kenneth T. Mills Buying and Selling Activity at REGENXBIO

REGENXBIO Company Overview

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Today's Range

Now: $8.21

$8.13

$8.65

50 Day Range

MA: $7.36

$5.92

$8.70

2 Week Range

Now: $8.21

$5.62

$22.42

Volume

643,705 shs

Average Volume

712,573 shs

Market Capitalization

$411.21 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.35